Latest Resources

27 June 2006
Groups in Latin America and Africa call for rejection of World Bank GEF biosafety projects
Two World Bank projects, with funding from the GEF (Global Environmental Facility), propose to introduce genetically modified crops such as maize, potatoes, cassava, rice and cotton into African and Latin American countries that are centres of origin or diversity for these and other major food crops. Civil society organisations warn that DNA contamination from genetically […]

24 June 2006
Adenovirus type 5 with HIV gag, pol and nef genes / Chris Hani Baragwanath Hospital
Comments and Concerns on the application made by Prof. Glenda Gray in respect of HIV vaccine clinical trial of genetically modified organism (MRKAd5 HIV-1 gag/pol/nef) Comments and concerns It should be noted that this submission is written in the context of a country that is devastated by HIV-AIDS at every level. That solutions are needed […]

14 June 2006
LibertyLink-Rice / Bayer CropScience
Application Made By Bayer Cropscience Gmbh In Respect Of A Commodity Clearance Application For Event Llrice62 To The National Department Of Agriculture, South Africa African Centre for Biosafety, supported by various organisations, groups, companies, and individuals. Read here.

4 June 2006
Article 18(2)(a): The Trojan Horse of the Biosafety Protocol
Read the article here. By Mariam Mayet African Centre for Biosafety July 2006 The “may contain” labels flood the feed sector. Even transboundary movements which could pass as GM-free under existing legislation for LMO-FFPs are labelled as “may contain”. Grain trade and important ports are leading in this clever move which actually ridicules the Protocol. […]

4 June 2006
Pharma Crops and GE Vaccines
HIV Vaccine Clinical Trial Of Genetically Modified Organism (MRKAd5 HIV1 gag/pol/nef) African Centre for Biosafety Jun 2006. Read here. The Status Of Genetically Modified (gm) Pharmaceutical Crop Research In South Africa Mar 2006 Rose Williams. Read here.

29 May 2006
Bioethanol-Maize / Syngenta
COMMENTS BY THE AFRICAN CENTRE FOR BIOSAFETY AND THE CENTRE FOR FOOD SAFETY (USA) Comments on Syngenta’s Application for Commodity Clearance of Genetically Modified Maize, Event 3272 African Centre for Biosafety & Centre for Food Safety, 29 May 2006 Read here. OVERVIEW Syngenta’s Event 3272 maize represents the very first genetically modified (GM) industrial crop […]

6 May 2006
South Africa, Bioethanol and GMOs: A Heady Mixture
On the 12th of May 2006 Syngenta South Africa (Pty) Ltd, a subsidiary of Swiss chemical giant Syngenta, notified the public of its intention to seek commodity clearance for its GM maize for the use in the production of ethanol. This is the first GM application for commercial approval in the world for a non-feed, […]

1 March 2006
The status of Genetically Modified (GM) pharmaceutical crop research in South Africa
Genetically modified (GM) pharmaceutical crops are crops which have been genetically engineered / modified to produce pharmaceuticals. These pharmaceuticals can be vaccines, anti-bodies or therapeutic proteins. Pharma-crops (as they are known) are a contested and little-known terrain, with remarkable benefits being claimed for them in South Africa. Other voices ask about the contamination of the […]

7 February 2006
South Africans support international GM opposition day
Earthlife Africa (ELA) and the African Centre for Biosafety (ACB) are joining an international day of action on genetically modified organisms (GMOs) on Saturday the 8th of April, in demanding that GM food for sale in South Africa is labeled as such. Currently, South Africa’s labeling regulations do not require the mandatory labeling of GM […]

27 January 2006
Biohazard Map of GM Field Trials in SA
Now that the dust is settling after industry’s aggressive PR hype about the unsubstantiated increase in South Africa’s GM commercial plantings for 2006, we bring to you, based upon empirical data, a short briefing paper on the field trials of GMOs grown in South Africa during 2006, compiled by ACB researcher, Rose Williams. This briefing […]